Pharmaceuticals & Therapeutics

Cellular Intelligence assembles a powerhouse advisory board and acquires a Phase 2 Parkinson's therapy to build the first universal model of cell signaling.

As diabetic amputations rise globally, a micro-cap biotech enters Phase 2a trials with a novel topical gel designed to physically destroy drug-resistant superbugs.

Heavy menstrual bleeding drives 600,000 surgeries a year. Hemab Therapeutics aims to replace invasive treatments with a once-a-month injection.

Matisse Pharmaceuticals secures €14 million to advance a radically different approach to sepsis, targeting cytotoxic histones to stop organ failure.

Fennec Pharmaceuticals unveils compelling trial data showing its therapy prevents permanent hearing loss in children undergoing life-saving chemotherapy.

By pairing high fashion with complex pharmacology, Sun Pharma aims to capture a multi-billion dollar autoimmune market—but genetic testing and black-box warnings stand in the way.

Kathleen Cook explores how Axsome Therapeutics uses real-world data and novel therapies to solve the hardest problems in modern psychiatric and neurologic care.

After decades of regulatory gridlock, a breakthrough UV filter finally hits US shelves. Here is how it could end the reign of gray-market K-beauty imports.

SK Biopharmaceuticals and 1ST Biotherapeutics forge a $314.8M alliance to advance a novel dual-inhibitor, reshaping the global Parkinson's landscape.

For 30 years, hair loss treatments have been trapped in a hormonal stalemate. Rubedo Life Sciences is betting its AI-driven senolytic platform can change that.

Newly independent Ennature Biopharma is betting on validated science for its botanicals, aiming to lead the booming women's health market with transparency.

After decades of setbacks, a new drug from Skyhawk Therapeutics shows patients not just slowing decline, but improving. Is this the breakthrough a desperate community has been waiting for?

As temperatures drop, many pet owners stop parasite prevention. Experts warn this is a costly mistake for a pet's health and the household's well-being.

A landmark partnership will use a twice-yearly injection and a powerful regional fund to combat rising HIV rates across Latin America and the Caribbean.

In the race for a 'longevity protein' therapy, a key safety milestone is met. This de-risks the path to the clinic, but what does it mean for the future?

Biodexa nets $2.3M in a complex warrant deal, buying runway for its cancer and diabetes drugs at the steep price of massive potential shareholder dilution.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

With impressive Phase 2 data, Revelyx Bio's ready-to-use recombinant toxin YY003 signals a major technological and practical shift for the aesthetics industry.